
Overview
Biopharmaceutical firm's Q4 revenue rose 28% yr/yr, beating analyst expectations
Adjusted EPS for Q4 missed analyst expectations
Company's revenue growth driven by demand for Jakafi and Opzelura
Outlook
Incyte projects 2026 total net product revenue between $4.77 bln and $4.94 bln
Company expects Jakafi net product revenue of $3.22 bln to $3.27 bln in 2026
Incyte anticipates Opzelura net product revenue of $750 mln to $790 mln in 2026
Result Drivers
PRODUCT DEMAND - Increased demand for Jakafi and Opzelura drove net product revenue growth in Q4 2025
NEW PRODUCT UPTAKE - Strong uptake of Niktimvo and Zynyz contributed to revenue growth
MILESTONE REVENUE - Milestone and contract revenue added $100 mln to Q4 total revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $1.51 bln | $1.35 bln (20 Analysts) |
Q4 Adjusted EPS | Miss | $1.80 | $1.93 (17 Analysts) |
Q4 EPS |
| $1.46 |
|
Q4 Adjusted Operating Income | Miss | $451.42 mln | $473.06 mln (10 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Incyte Corp is $108.50, about 0.5% below its February 9 closing price of $109.03
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago
Press Release: ID:nBwbbn8FRa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.